Redemption: 2023-03-15; Registration: 144A/Reg S; Comments: 02/17/2021 IQVIA Inc (IQV) EUR1.45bn 144A/Reg S sr notes 2-part. Ba3/BB (stable/stable). Via JPM (sole physical books, B&D)/Barc/BofA/GS/HSBC/WFS joint books, Citi, FITB, PNC, Mizuho, MUFG, TD, TSI, BBVA, BNPP, Huntington, RBC, Siebert Willliams as co-managers. No reg rights. List ISE. NY law. Settles 03/03 (T+10). - EUR550m (from minimum EUR400m) due 03/15/26 (5y). NC2 (03/15/23) (MWC B+50bp), then at 100.875, 100.438, 100. Equity claw: 2y 40% at 101.75. Reg S ISIN: XS2305742434. IPT: 2.00%-2.25%. Px talk: 1.75%-1.875%. Final pricing: EUR550m at 1.75%. Priced: 1.75% at 100. +240bp vs DBR 0.5% 02/15/26. - EUR900m due 03/15/29 (8y). NC3 (MWC B+50bp), then at 101.125, 100.563, 100. Equity claw: 3y 40% at 102.25. Reg S ISIN: XS2305744059. IPT: 2.50% area. Px talk: 2.25%-2.50%. Final pricing: EUR900m at 2.25%. Priced: 2.25% at 100. +273bp vs DBR 0.25% 02/5/29. Did global investor call at 1pm UKT 02/16 (virtual 1x1 meetings were also available 02/16). Books closed at 2pm UKT 0217. UOP: redeem its EUR1.425bn 3.25% sr notes due 03/15/25 (callable at 100.813 on 03/15/21). Biz: leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. HQ: Durham, NC and Danbury, CT.; Redemption: 2024-03-15; Registration: 144A/Reg S; Comments: 02/17/2021 IQVIA Inc (IQV) EUR1.45bn 144A/Reg S sr notes 2-part. Ba3/BB (stable/stable). Via JPM (sole physical books, B&D)/Barc/BofA/GS/HSBC/WFS joint books, Citi, FITB, PNC, Mizuho, MUFG, TD, TSI, BBVA, BNPP, Huntington, RBC, Siebert Willliams as co-managers. No reg rights. List ISE. NY law. Settles 03/03 (T+10). - EUR550m (from minimum EUR400m) due 03/15/26 (5y). NC2 (03/15/23) (MWC B+50bp), then at 100.875, 100.438, 100. Equity claw: 2y 40% at 101.75. Reg S ISIN: XS2305742434. IPT: 2.00%-2.25%. Px talk: 1.75%-1.875%. Final pricing: EUR550m at 1.75%. Priced: 1.75% at 100. +240bp vs DBR 0.5% 02/15/26. - EUR900m due 03/15/29 (8y). NC3 (MWC B+50bp), then at 101.125, 100.563, 100. Equity claw: 3y 40% at 102.25. Reg S ISIN: XS2305744059. IPT: 2.50% area. Px talk: 2.25%-2.50%. Final pricing: EUR900m at 2.25%. Priced: 2.25% at 100. +273bp vs DBR 0.25% 02/5/29. Did global investor call at 1pm UKT 02/16 (virtual 1x1 meetings were also available 02/16). Books closed at 2pm UKT 0217. UOP: redeem its EUR1.425bn 3.25% sr notes due 03/15/25 (callable at 100.813 on 03/15/21). Biz: leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. HQ: Durham, NC and Danbury, CT.;